Orrick Advises OKYO Pharma on U.S. Initial Public Offering


London capital markets partners Ed Lukins and Ed Dyson, supported by managing associate Charlotte Osborne, advised OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain incorporated in the Bailiwick of Guernsey, on its initial U.S. public offering on the Nasdaq Capital Market of 625,000 American Depositary Shares, each representing 65 ordinary shares of no par value.